mgh_logo

Harvard-Medical-School-logo

Generic filters

fezolinetant

FDA Accepts New Drug Application for Fezolinetant, A Novel Nonhormonal Treatment for Vasomotor Symptoms

The FDA accepted a New Drug Application for fezolinetant, a novel, nonhormonal selective neurokinin-3 receptor (NK3R) antagonist for the treatment of menopause-related vasomotor symptoms.

By |2022-08-29T14:26:08-04:00August 26th, 2022|Medication, Menopausal Symptoms, Treatment, Vasomotor Symptoms|Comments Off on FDA Accepts New Drug Application for Fezolinetant, A Novel Nonhormonal Treatment for Vasomotor Symptoms
Read More

Neurokinin Receptor Antagonists for the Treatment of Menopausal Symptoms

About 80% of women experience vasomotor symptoms (VMS) – hot flashes and night sweats — as they transition into the menopause phase.  For most, the symptoms are manageable, but for a sizeable subset of midlife [...]

By |2020-02-29T11:39:05-04:00October 15th, 2019|Menopausal Symptoms|Comments Off on Neurokinin Receptor Antagonists for the Treatment of Menopausal Symptoms
Read More
Copyright 2026 MGH Center for Women's Mental Health | All Rights Reserved
Go to Top